Karen Firestone - 16 Mar 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Director
Signature: /s/ Joshua B. Cohen, as Attorney in Fact
Issuer symbol: AMLX
Transactions as of: 16 Mar 2023
Net transactions value: +$31,990
Form type: 4
Filing time: 20 Mar 2023, 20:22:25 UTC
Next filing: 12 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMLX	Common Stock	Purchase	$31,990	+1,000		$31.99	1,000	16 Mar 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMLX	Stock Option (Right to Buy)	Award	$0	+27,403		$0.000000	27,403	16 Mar 2023	Common Stock	27,403	$32.08	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.96 to $32.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request
F2	One-third of the shares subject to the option shall vest on the first anniversary of the date of grant, and the remaining two-thirds will vest in equal monthly installments over two years, provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director of the Issuer.